AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10200005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone at 2 mg/kg/dose (maximum 120 mg/dose) twice daily
Number of subjects: 66
Study 10200005 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone at 1 mg/kg/dose (maximum 60 mg/dose) four times daily
Number of subjects: 66
Study 8659482 — intervention group
Group type: EXPERIMENTAL
Intervention: Low animal protein, high fiber diet (56-64 g daily protein, 75 mg daily purine, one-fourth cup of wheat bran, fruits and vegetables) with instructions to drink six to eight glasses of liquid daily and maintain adequate calcium intake.
Number of subjects: 99
Study 8659482 — intervention group
Group type: COMPARATOR
Intervention: Control group received advice only on fluid intake and adequate calcium intake.
Number of subjects: 99
Study 8659482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received a mean of 3.4 person-years of follow-up.
Number of subjects: 99
Study 1825568 — intervention group
Group type: EXPERIMENTAL
Intervention: GR32191 (80 mg po and 40 mg po)
Number of subjects: 24
Study 1825568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6833519 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 49
Study 6833519 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 49
Study 6833519 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine and Amitriptyline
Number of subjects: 49
Study 6833519 — intervention group
Group type: EXPERIMENTAL
Intervention: High pretreatment MHPG excretion
Number of subjects: 49
Study 6833519 — intervention group
Group type: EXPERIMENTAL
Intervention: MHPG excretion
Number of subjects: 49
Study 6833519 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography method vs gas chromatography/mass spectrometry
Number of subjects: 49
Study 30770307 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pioglitazone (45 mg per day)
Number of subjects: 40
Study 30770307 — intervention group
Group type: COMPARATOR
Intervention: Standard induction chemotherapy (cytarabine 100 mg/m2 per day for 7 days and daunorubicin 60 mg/m2 per day for 3 days)
Number of subjects: 40
Study 29199012 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of CLS‐TA with intravitreal injection of aflibercept (combination arm)
Number of subjects: 38
Study 29199012 — intervention group
Group type: COMPARATOR
Intervention: Only intravitreal injection of aflibercept (monotherapy arm)
Number of subjects: 38
Study 29199012 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of CLS‐TA
Number of subjects: 38
Study 26896291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS) fermented milk
Number of subjects: 0
Study 26896291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS)
Number of subjects: 0
Study 26896291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25244776 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupingfeng droppill and cetirizine tablets
Number of subjects: 76
Study 25244776 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine tablets
Number of subjects: 76
Study 21877203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel (CT cohort)
Number of subjects: 200
Study 21877203 — intervention group
Group type: COMPARATOR
Intervention: NCT cohort (control)
Number of subjects: 200
Study 19761998 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 562
Study 19761998 — intervention group
Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 562
Study 17617809 — intervention group
Group type: EXPERIMENTAL
Intervention: Home dampness
Number of subjects: 6794
Study 17617809 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible presence of mold
Number of subjects: 6794
Study 14687747 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic reinforcement during postoperative counselling
Number of subjects: 233
Study 14687747 — intervention group
Group type: COMPARATOR
Intervention: Control group (no photographic reinforcement)
Number of subjects: 233
Study 12209372 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (yoghurt enriched with L. acidophilus 145, B. longum 913 and 1% oligofructose)
Number of subjects: 29
Study 12209372 — intervention group
Group type: COMPARATOR
Intervention: Control yoghurt (yoghurt without probiotics)
Number of subjects: 29
Study 9827838 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call 1 week after the emergency department visit
Number of subjects: 0
Study 9827838 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call 2 weeks after the visit
Number of subjects: 0
Study 9827838 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call 4 weeks after the visit
Number of subjects: 0
Study 10023014 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous epoetin á 150 U/kg three times a week for up to 12 consecutive weeks (Group A)
Number of subjects: 20
Study 10023014 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous epoetin á 50 U/kg daily for up to 12 consecutive weeks (Group B)
Number of subjects: 20
Study 10023014 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 20
Study 10023014 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 20
Study 2676173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release isosorbide-5-mononitrate (ISM) 60 mg
Number of subjects: 9
Study 2676173 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study 343273 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice a day
Number of subjects: 15
Study 343273 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg twice a day
Number of subjects: 15
Study 31065919 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gastric bypass
Number of subjects: 113
Study 31065919 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal gastric bypass
Number of subjects: 113
Study 27941058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous exenatide
Number of subjects: 9
Study 25407260 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine slow-release tablets 20 mg 4 times daily
Number of subjects: 8
Study 25407260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 23062214 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus Azathioprine
Number of subjects: 56
Study 23062214 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone plus placebo
Number of subjects: 56
Study 20938351 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz ultrabrief-pulse ECT
Number of subjects: 40
Study 20938351 — intervention group
Group type: COMPARATOR
Intervention: 100 Hz ultrabrief-pulse ECT
Number of subjects: 40
Study 19403992 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1,800 mg daily
Number of subjects: 126
Study 16362479 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrojejunostomy (LGJ)
Number of subjects: 27
Study 16362479 — intervention group
Group type: COMPARATOR
Intervention: Duodenal stenting (DS)
Number of subjects: 27
Study 15213620 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) administered from 2 days before until day 7 after esophagectomy, standard doses
Number of subjects: 155
Study 15213620 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered from 2 days before until day 7 after esophagectomy
Number of subjects: 155
Study 11304934 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin-ratiopharm 25 mg film-coated tablets (test preparation)
Number of subjects: 30
Study 11304934 — intervention group
Group type: COMPARATOR
Intervention: 25 mg dragées of the reference preparation (control)
Number of subjects: 30
Study 9519098 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 60
Study 9519098 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 60
Study 7684422 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZCHH380
Number of subjects: 20
Study 7684422 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 20
Study 3552464 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 15
Study 3552464 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 15
Study 3552464 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg albuterol (Salbutamol)
Number of subjects: 15
Study 29346473 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in primary care
Number of subjects: 288
Study 29346473 — intervention group
Group type: COMPARATOR
Intervention: Specialist care
Number of subjects: 288
Study 27286829 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led triage
Number of subjects: 163
Study 27286829 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 163
Study 24116853 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) 20-150 mg/day
Number of subjects: 480
Study 24116853 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV)
Number of subjects: 480
Study 24116853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 480
Study 22424659 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Dai trained TBAs
Number of subjects: 545
Study 22424659 — intervention group
Group type: COMPARATOR
Intervention: Untrained TBAs
Number of subjects: 545
Study 19880139 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 86
Study 19880139 — intervention group
Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 86
Study 18587525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu-(II)-orotate-dihydrate; 8 mg Cu daily
Number of subjects: 68
Study 18587525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 15863433 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider tobacco prevention advice
Number of subjects: 4026
Study 15863433 — intervention group
Group type: COMPARATOR
Intervention: Tobacco prevention messages from school
Number of subjects: 4026
Study 15863433 — intervention group
Group type: COMPARATOR
Intervention: Tobacco prevention messages from parents
Number of subjects: 4026
Study 15863433 — intervention group
Group type: COMPARATOR
Intervention: Tobacco prevention messages from mass media
Number of subjects: 4026
Study 11874243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal SCT (200 IU daily)
Number of subjects: 28
Study 11874243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10403877 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 0
Study 10403877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ametop
Number of subjects: 0
Study 10403877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8868206 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg bid, p.o.)
Number of subjects: 0
Study 8868206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2346342 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal administration of atropine
Number of subjects: 20
Study 2346342 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of atropine
Number of subjects: 20
Study 4607227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal immunization with inactivated influenza virus vaccine (monovalent or bivalent)
Number of subjects: 10000
Study 4607227 — intervention group
Group type: COMPARATOR
Intervention: Intranasal immunization with inactivated influenza virus vaccine (placebo)
Number of subjects: 10000
Study 31951747 — intervention group
Group type: EXPERIMENTAL
Intervention: HG alert tool in electronic health record system
Number of subjects: 3350
Study 31951747 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alerts shown)
Number of subjects: 3350
Study 30142373 — intervention group
Group type: EXPERIMENTAL
Intervention: Drusenoid pigment epithelial detachment (DPED)
Number of subjects: 325
Study 30142373 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMS2 risk alleles
Number of subjects: 325
Study 30142373 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing genetic risk score (GRS) group
Number of subjects: 325
Study 28525555 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 180 mg/day
Number of subjects: 320
Study 28525555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 26437720 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school dance intervention (up to 40 sessions of 75 minutes each over 20 weeks)
Number of subjects: 571
Study 24621799 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) mode
Number of subjects: 23
Study 24621799 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) mode
Number of subjects: 23
Study 21697706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention delivered via Web site and handheld computer
Number of subjects: 74
Study 21697706 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld computer usage
Number of subjects: 74
Study 21697706 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge scores
Number of subjects: 74
Study 21697706 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy scores
Number of subjects: 74
Study 21697706 — intervention group
Group type: EXPERIMENTAL
Intervention: Web site use
Number of subjects: 74
Study 21697706 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld computer usage frequency
Number of subjects: 74
Study 19252346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day) + Sibutramine (10 mg/day)
Number of subjects: 105
Study 19252346 — intervention group
Group type: COMPARATOR
Intervention: Metformin (3,000 mg/day) + Sibutramine (10 mg/day)
Number of subjects: 105
Study 19252346 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study 16298763 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol (480 mg) and vitamin C (60 mg)
Number of subjects: 44
Study 16298763 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (60 mg) alone
Number of subjects: 44
Study 14768237 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl Rapide
Number of subjects: 120
Study 14768237 — intervention group
Group type: COMPARATOR
Intervention: Safil Quick
Number of subjects: 120
Study 11506097 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 24
Study 11506097 — intervention group
Group type: COMPARATOR
Intervention: midazolam
Number of subjects: 24
Study 9230823 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 374
Study 9230823 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 374
Study 8431330 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (end‐tidal)
Number of subjects: 38
Study 8431330 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (end‐tidal)
Number of subjects: 38
Study 8431330 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen
Number of subjects: 38
Study 8431330 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 3-10 mg
Number of subjects: 38
Study 8431330 — intervention group
Group type: COMPARATOR
Intervention: i.v. technique
Number of subjects: 38
Study 8431330 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 38
Study 8431330 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 38
Study 8431330 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic technique
Number of subjects: 38
Study 3583405 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (specific inhibitor of neuronal uptake)
Number of subjects: 11
Study 3583405 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (1.18 pmol/kg/min) with desipramine
Number of subjects: 11
Study 3583405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (various doses) during desipramine inhibition
Number of subjects: 11
Study 3583405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (highest dose without neuronal uptake inhibition)
Number of subjects: 11
Study 28709817 — intervention group
Group type: EXPERIMENTAL
Intervention: First line treatment with daily oral antihistamine
Number of subjects: 150
Study 28709817 — intervention group
Group type: EXPERIMENTAL
Intervention: Second line treatment with higher dose antihistamine
Number of subjects: 150
Study 28709817 — intervention group
Group type: EXPERIMENTAL
Intervention: Third line treatment with omalizumab or cyclosporine
Number of subjects: 150
Study 28709817 — intervention group
Group type: COMPARATOR
Intervention: First line treatment
Number of subjects: 150
Study 28777519 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention with HBO₂ therapy (Group 2)
Number of subjects: 22
Study 28777519 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention without HBO₂ therapy (Group 1)
Number of subjects: 22
Study 26581687 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week 'self‐selected' supervised exercise training programme with dietary advice
Number of subjects: 360
Study 26581687 — intervention group
Group type: COMPARATOR
Intervention: General information on lifestyle and diabetes risk
Number of subjects: 360
Study 23682517 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butyl-2-cyanoacrylate (Histoacryl)
Number of subjects: 60
Study 23682517 — intervention group
Group type: COMPARATOR
Intervention: Staple fixation
Number of subjects: 60
Study 20528605 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma communication education intervention (ACE)
Number of subjects: 231
Study 20528605 — intervention group
Group type: COMPARATOR
Intervention: Asthma education control group (CON)
Number of subjects: 231
Study 20528605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ACE and CON)
Number of subjects: 231
Study 19139247 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced caregiver support intervention
Number of subjects: 254
Study 19139247 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 254
Study 16689065 — intervention group
Group type: COMPARATOR
Intervention: No liner or base
Number of subjects: 40
Study 16689065 — intervention group
Group type: EXPERIMENTAL
Intervention: Liner only
Number of subjects: 40
Study 16689065 — intervention group
Group type: EXPERIMENTAL
Intervention: Base only
Number of subjects: 40
Study 16689065 — intervention group
Group type: EXPERIMENTAL
Intervention: Base and liner
Number of subjects: 40
Study 15305893 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal septicaemia
Number of subjects: 24
Study 15305893 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal septicaemia with pulmonary oedema
Number of subjects: 24
Study 15305893 — intervention group
Group type: COMPARATOR
Intervention: Controls with noninfectious critical illness
Number of subjects: 24
Study 11587207 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC3 regimen (2‐CdA 0.12 mg/kg for 3 days, mitoxantrone 10 mg/m2 on day 1, cyclophosphamide 650 mg/m2 on day 1)
Number of subjects: 62
Study 11587207 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC5 regimen (2‐CdA 0.12 mg/kg for 5 days, mitoxantrone 10 mg/m2 on day 1, cyclophosphamide 650 mg/m2 on day 1)
Number of subjects: 62
Study 11587207 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC5 regimen
Number of subjects: 62
Study 11587207 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC3 regimen
Number of subjects: 62
Study 9436689 — intervention group
Group type: EXPERIMENTAL
Intervention: Long GnRH‐a
Number of subjects: 60
Study 9436689 — intervention group
Group type: EXPERIMENTAL
Intervention: Short GnRH‐a
Number of subjects: 60
Study 9436689 — intervention group
Group type: EXPERIMENTAL
Intervention: No GnRH‐a
Number of subjects: 60
Study 9436689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (after embryo transfer)
Number of subjects: 60
Study 9436689 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant patients
Number of subjects: 60
Study 8011571 — intervention group
Group type: EXPERIMENTAL
Intervention: Anipamil 80 mg once daily
Number of subjects: 19
Study 8011571 — intervention group
Group type: EXPERIMENTAL
Intervention: Anipamil 160 mg once daily
Number of subjects: 19
Study 8011571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2442550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS) 20, 40, and 80 mg
Number of subjects: 394
Study 2442550 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5, 25, and 50 mg
Number of subjects: 394
Study 2442550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril + Hydrochlorothiazide (LIS + HCTZ) 20 + 12.5, 40 + 25, and 80 + 50 mg
Number of subjects: 394
Study 31822399 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (35 or 50 mg/m2 twice‐weekly [BIW] or 50 mg/m2 once‐weekly [QW])
Number of subjects: 114
Study 31822399 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (50 mg/m2 QW)
Number of subjects: 114
Study 31822399 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor
Number of subjects: 114
Study 30768411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for anxiety
Number of subjects: 80
Study 30768411 — intervention group
Group type: COMPARATOR
Intervention: Child-centered therapy (CCT)
Number of subjects: 80
Study 28238674 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory Action Research (PAR) weekly sessions
Number of subjects: 30
Study 28238674 — intervention group
Group type: COMPARATOR
Intervention: Active control (weekly reminiscence activity)
Number of subjects: 30
Study 28238674 — intervention group
Group type: COMPARATOR
Intervention: Passive control (care as usual)
Number of subjects: 30
Study 28238674 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative experience of PAR participants
Number of subjects: 30
Study 25928739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (attendance incentives)
Number of subjects: 1300